• Allogene Therapeutics Inc ALLO.OQ reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -38 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -36 cents to -25 cents per share.

• Reported revenue was zero​; analysts expected $1.82 thousand.

• Allogene Therapeutics Inc's reported EPS for the quarter was a loss of 28 cents​.

• The company reported a quarterly loss of $59.73 million.

• Allogene Therapeutics Inc shares had fallen by 19.9% this quarter and lost 45.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 12% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Allogene Therapeutics Inc is $9.00

This summary was machine generated from LSEG data May 13 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)